In vitro study demonstrates lutetium nanoscintillators enhance radiotherapy via physical dose escalation and impaired DNA repair in pancreatic cancer models, highlighting a dual radiosensitizing...
Rationale: Pancreatic cancer has a dismal prognosis and requires better treatments.One promising approach aims at improving radiotherapy using nanoscintillators, which down-convert ionizing radiation into visible light, triggering various radiotherapeutic effects upon X-ray irradiation.One such effect is radiation dose-enhancement, driven by high-Z elements present in the nanoscintillator core.These elements efficiently absorb X-rays, releasing secondary electrons that amplify the radiation dose in the surrounding tissue.Methods: In this paper, we study the ability of Lu3Al5O12:Pr@SiO2, a lutetium-based nanoscintillator, to exert a radiation dose-enhancement effect in two human pancreatic cancer cell models, namely PANC-1 and MIA PaCa-2.Results: Lu3Al5O12:Pr@SiO2 nanoparticles showed negligible toxicity up to 1 mg/mL in 2D and 3D models.Using monochromatic synchrotron radiation, we demonstrated that a subtoxic nanoparticle concentration enhances the radiation dose in 3D spheroids in an energy-dependent manner.These results were further supported by Monte Carlo simulations.Beyond this physical contribution, γ-H2AX foci quantification revealed a biological component to the radiosensitization: Lu3Al5O12:Pr@SiO2 nanoparticles not only amplified initial DNA damage, but also impaired its repair.Conclusion: These findings highlight the dual contribution of Lu3Al5O12:Pr@SiO2 nanoparticles to radiotherapy enhancement, combining both physical dose-enhancement and biological modulation of DNA repair.
No takes yet. Share an insight, caveat, or question.
Stelse‐Masson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: